<DOC>
	<DOCNO>NCT02989493</DOCNO>
	<brief_summary>Double-blind , placebo control , randomize control trial ( RCT ) Alcohol Use Disorder examine effect doxazosin , norepinephrine alpha1 receptor antagonist , stress reactivity clinical outcome .</brief_summary>
	<brief_title>Testing Doxazosin Treat Stress Mechanisms Alcoholism</brief_title>
	<detailed_description>OBJECTIVES : 1 . To translate preclinical evidence animal model stress-induced relapse human via direct pharmacological antagonism noradrenergic system abstinent alcoholic doxazosin , alpha1 noradrenergic receptor blocker . 2 . To screen efficacy doxazosin target stress-related relapse mechanism abstinent alcoholic cost-effective first step repurpose alpha1 noradrenergic antagonist relapse prevention addiction . PARTICIPANTS : 136 participant Alcohol Use Disorder early abstinence . STUDY OVERVIEW : 136 adult Alcohol Use Disorder early abstinence ( 1-8 week abstinent ) participate randomize controlled trial ( RCT ) examine efficacy 8 mg doxazosin ( vs. placebo , between-subjects ) stress reactivity clinical outcome measure ( e.g. , drinks/week , alcohol crave ) 8 week treatment period . We assess doxazosin 's impact stress-related relapse mechanism use well-validated human model stressor reactivity ( No Shock , Predictable Shock , Unpredictable Shock [ NPU ] task ) baseline ( pre-treatment ) 4 week treatment . The NPU task strong translational tie method ( e.g. , unpredictable vs. predictable electric shock ) measure ( e.g. , startle potentiation ) preclinical literature animal . This laboratory stress task serve attractive early surrogate endpoint post-treatment ass treatment efficacy examine stress mechanism . AIMS HYPOTHESIS : AIM 1 : Examine effect therapeutic dose doxazosin response unpredictable stressor NPU task . The aim obtain preliminary evidence via laboratory surrogate endpoint repurpose doxazosin treatment stress-induced relapse mechanism alcoholism . PREDICTIONS : Following four week therapeutic dosing , doxazosin ( 8 mg vs. placebo , between-subjects ) selectively reduce response unpredictable ( vs. predictable ) stressor indexed physiological defensive reactivity ( startle potentiation ) self-reported negative affect crave abstinent alcoholic . AIM 2 : Examine effect therapeutic dose doxazosin early clinical outcome measure . The aim obtain additional evidence via clinical outcome measure repurpose doxazosin treatment stress-induced relapse mechanism alcoholism . PREDICTIONS : Following eight week therapeutic dosing , doxazosin ( 8 mg vs. placebo , between-subjects ) increase continuous abstinence decrease drinking day per week drink per week medication treatment period . Doxazosin also decrease crave measure 8th week medication use participant achieve maximum dose 4.5 week . AIM 3 : Examine predictive validity pre-treatment laboratory test noradrenergic relevant stress-reactivity surrogate endpoint clinical outcome measure . The aim link individual difference stress reactivity baseline ( i.e . pre-treatment ) laboratory surrogate endpoint early clinical outcome measure follow therapeutic dosing . PREDICTIONS : Higher pre-treatment reactivity unpredictable stressor predict poor surrogate endpoint clinical outcome overall . Therapeutic 8 mg dose effect doxazosin great among alcoholic display high pre-treatment reactivity unpredictable stressor . AIM 4 : Examine effect doxazosin clinical outcome measure mediate reduction stress-reactivity measure NPU task . The aim identify whether reduction stress-reactivity ( NPU task ) mechanism doxazosin effect drink behavior ( clinical outcome ) . PREDICTIONS : The direct effect doxazosin ( vs. placebo ) follow 8 week therapeutic 8 mg dose clinical outcome ( e.g. , continuous abstinence , drink days/week , drinks/week ) partially mediate indirect effect doxazosin surrogate endpoint NPU stress reactivity 4 week .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnostic Statistical Manual ( DSM5 ) diagnosis Alcohol Use Disorder , ModerateSevere Alcohol abstinent 1 8 week Ages 18 65 Exclusion criterion divide three broad category Medical , Psychiatric/Behavioral , Medications/Therapies . EXCLUSION CRITERIA : Medical Blood alcohol concentration 0.00 . Color blind . Heart rate &gt; 100 beat per minute five minute seat . Heart rate &lt; 55 beat per minute five minute seat . Systolic BP &lt; 100 five minute seat . Systolic BP drop &gt; 20mm Hg diastolic BP drop &gt; 10mm Hg two minute stand . Dizziness , lightheadedness , unsteadiness problem ( e.g , nausea , blurry vision ) two minute stand . Uncorrected auditory/vision problem . Current treatment chronic pain condition . Past current coronary artery disease , cerebrovascular accident , congestive heart failure . Current chronic renal insufficiency , liver insufficiency moderate hepatic impairment , pancreatitis , immunosuppressive therapy , cancer systemic effect therapy . Benign positional vertigo , Meniere 's disease , narcolepsy . Previous allergic adverse reaction doxazosin alpha1 noradrenergic antagonist . Scheduled report plan cataract surgery prior study completion . Currently symptomatic alcohol withdrawal [ Clinical Institute Withdrawal Assessment Alcohol , revise ( CIWAAr ) Score &gt; 10 , positive 'visual , auditory tactile disturbance , ' 'orientation cloud sensorium ' ] Discharged inpatient treatment Alcohol Use Disorder alcohol detoxification within past 7 day . Currently medically unstable . Electrocardiogram ( ECG ) clinical overread indicate concern cardiac function . Other selfreported acute unstable illness , opinion study team , would preclude safe reliable study participation EXCLUSION CRITERIA : Female Participants Only Nonnegative urine pregnancy test . Women childbearing potential ( see definition ) must agree use one follow form birth control study completion . Acceptable birth control define follow method contraception : abstinence ; hormonal contraceptive ( e.g . combine oral contraceptive , patch , vaginal ring , injectables , implant ) ; intrauterine device ( IUD ) intrauterine system ( IUS ) ; vasectomy partner tubal ligation ; `` single '' barrier method contraception ( e.g . male condom , female condom , cervical cap , diaphragm , contraceptive sponge ) use spermicide ; `` double barrier '' method contraception ( e.g . male condom diaphragm , male condom cervical cap ) . Breastfeeding . NOTE : Women childbearing potential female experience menarche meet criterion woman childbearing potential . Women childbearing potential female permanently sterile ( e.g. , hysterectomy , bilateral oophorectomy ) postmenopausal . Postmenopausal define 12 consecutive month menses without alternative medical cause . EXCLUSION CRITERIA : Psychological/Behavioral Selfreported lifetime diagnosis schizophrenia , schizoaffective disorder , psychotic disorder otherwise specify , bipolar disorder ( manic episode ) , borderline personality disorder , neurocognitive disorder may impair reliable , safe participation . Current suicidal ideation . Current active substance use disorder alcohol tobacco . EXCLUSION CRITERIA : Medications/Therapies Currently prescribe use within past week : doxazosin alpha1 noradrenergic antagonist ( e.g. , prazosin , terazosin ) . Currently prescribe use within past week : substance stimulant property ( e.g. , damphetamine , methylphenidate , ephedra , pseudoephedrine ) . Currently prescribe use within past week : Sildenafil ( Viagra ) , tadalafil ( Cialis ) , vardenafil ( Levitra ) . Currently prescribe use within past week : betablockers ( e.g. , propanolol ) , alpha2 agonist ( e.g. , clonidine , guanfacine , dexmedetomidine ) , serotonin norepinephrine reuptake inhibitor ( SNRI ) ( e.g. , venlafaxine , duloxetine , atomoxetine , viloxazine ) . Currently use daily use within past week : alpha1 agonist ( e.g. , midodrine , metaraminol , oxymetazoline , phenylephrine ) . Currently use daily use within past week : Benzodiazepines ( e.g. , diazepam , chlordiazepoxide , lorazepam , clonazepam , alprazolam ) , zolpidem ( Ambien ) , zaleplon ( Sonata ) , zopiclone ( Imovane ) , eszopiclone ( Lunesta ) , doxepin ( Silenor ) . Currently prescribe use daily use within past 2 week : Trazodone . Currently prescribe use within 2 week : Disulfiram ( Antabuse ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Stress</keyword>
	<keyword>Norepinephrine</keyword>
	<keyword>Doxazosin</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Startle Potentiation</keyword>
	<keyword>Relapse</keyword>
	<keyword>Adrenergic Antagonists</keyword>
	<keyword>Surrogate Endpoint</keyword>
</DOC>